

## HAB HIV Performance Measures: ADAP: AIDS Drug Assistance Program

<b>Performance Measure: ADAP: Formulary</b>	
Percentage of new anti-retroviral classes that are included in the ADAP formulary within 90 days of the date of inclusion of new anti-retroviral classes in the PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents <sup>1</sup> during the measurement year.	
<b>Numerator</b>	Number of new anti-retroviral classes included into the ADAP formulary within 90 days of the publication of updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents that include new anti-retroviral drug class during the measurement year.
<b>Denominator:</b>	Total number of new antiretroviral classes published in updated PHS Guidelines during the measurement year.
<b>Exclusions:</b>	1. PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents published in the last 90 days of the measurement year.
<b>Data Element:</b>	1. Did the updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents include any new anti-retroviral classes? (Y/N) <ol style="list-style-type: none"> <li>a. If yes, (for each new class) was the new class included into the ADAP formulary within 90 days of publication of updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents? (Y/N)               <ol style="list-style-type: none"> <li>i. If yes, list the date of publication of PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents and date of inclusion in the ADAP formulary.</li> </ol> </li> </ol>
<b>Data Sources:</b>	<ul style="list-style-type: none"> <li>• AIDS Drug Assistance Program Quarterly Data Report</li> <li>• PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents</li> </ul>
<b>National Goals, Targets, or Benchmarks for Comparison:</b>	None available at this time.
<b>Basis for Selection:</b>	
The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415) <sup>2</sup> mandates that the state-operated ADAP programs “shall ensure that the therapeutics included on the list of classes of core antiretroviral therapeutics established by the Secretary under subsection (e) are, at a minimum, the treatments provided by the State pursuant to this section”. All ADAPs must include agents from each of the core antiretroviral classes listed in PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents <sup>3, 4</sup> . These legislative and policy requirements have also been specified in the Part B ADAP Grant Application <sup>5</sup> .	
<b>US Public Health Service Guidelines:</b>	
US Public Health Service Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and	

## HAB HIV Performance Measures: ADAP: AIDS Drug Assistance Program

### Performance Measure: ADAP: Formulary

Adolescents<sup>1</sup> contains the list of classes of core antiretroviral therapeutics to be included in ADAP formularies.

#### References/Notes:

<sup>1</sup> Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161.. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed December 7, 2009.

<sup>2</sup> The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415), Section 202(a).

<sup>3</sup> HRSA/HAB, Policy Notice-07-03, “The Use of Ryan White HIV/AIDS Program, Part B (formerly Title II), AIDS Drug Assistance Program (ADAP) Funds for Access, Adherence and Monitoring Services”, September 2007

<sup>4</sup> Deborah Parham Hopson, Ph.D., R.N., Assistant Surgeon General, Associate Administrator, HIV/AIDS Bureau, HRSA letter to Part B Grantees, February 1, 2008.

<sup>5</sup> HRSA/HAB Division of Service Systems Program Guidance: HIV Care Grant Program Part B: States/Territories Formula and Supplemental Awards and AIDS Drug Assistance Program Formula and Supplemental Awards, HRSA Announcement Numbers: HRSA 09-182 and 09-183.